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The plasma levels of high-density lipoprotein cholesterol (HDL) have an inverse relationship
to the risks of atherosclerosis and cardiovascular disease (CVD), and have also been
associated with longevity. We sought to identify novel loci for HDL that could potentially
provide new insights into biological regulation of HDL metabolism in healthy-longevous
subjects. We performed a genome-wide association (GWA) scan on HDL using a mixed
model approach to account for family structure using kinship coefficients. A total of
4114 subjects of European descent (480 families) were genotyped at ∼2.3 million SNPs
and ∼38 million SNPs were imputed using the 1000 Genome Cosmopolitan reference
panel in MACH. We identified novel variants near-NLRP1 (17p13) associated with an
increase of HDL levels at genome-wide significant level (p < 5.0E-08). Additionally, several
CETP (16q21) and ZNF259-APOA5-A4-C3-A1 (11q23.3) variants associated with HDL were
found, replicating those previously reported in the literature. A possible regulatory variant
upstream of NLRP1 that is associated with HDL in these elderly Long Life Family Study
(LLFS) subjects may also contribute to their longevity and health. Our NLRP1 intergenic
SNPs show a potential regulatory function in Encyclopedia of DNA Elements (ENCODE);
however, it is not clear whether they regulate NLRP1 or other more remote gene. NLRP1
plays an important role in the induction of apoptosis, and its inflammasome is critical
for mediating innate immune responses. Nlrp1a (a mouse ortholog of human NLRP1)
interacts with SREBP-1a (17p11) which has a fundamental role in lipid concentration
and composition, and is involved in innate immune response in macrophages. The
NLRP1 region is conserved in mammals, but also has evolved adaptively showing signals
of positive selection in European populations that might confer an advantage. NLRP1
intergenic SNPs have also been associated with immunity/inflammasome disorders which
highlights the biological importance of this chromosomal region.
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INTRODUCTION
Epidemiologic studies have shown that high plasma levels of high-
density lipoprotein cholesterol (HDL) have protective effects on
atherosclerosis and cardiovascular disease (CVD) across multi-
ple populations (Toth et al., 2013; Feig et al., 2014). HDL seems
to contribute to atheroprotection as an anti-inflammatory, and
is involved in a myriad of biologic processes, such as: promot-
ing reverse cholesterol transport, regulating plasma membrane
cholesterol content, mediating nitric oxide production in the
endothelium, inhibiting low-density lipoprotein cholesterol oxi-
dation, inhibiting the expression of proinflammatory cell adhe-
sion molecules on endothelial cell apoptosis, and modulating the
activity of macrophage chemotactic factors (Toth et al., 2013; Feig
et al., 2014). Recently, Feig et al. (2014) demonstrated evidence,
from preclinical and clinical studies, that HDL can promote the
regression of atherosclerosis when the levels of functional HDL
particles are increased, either by stimulating endogenous pro-
duction of (lipid-poor) apoAI or by providing HDL or apoAI
exogenously. In addition, there is evidence that HDL levels are
associated with longevity (Bergman et al., 2007; Koropatnick
et al., 2008; Newman et al., 2011; Rahilly-Tierney et al., 2011).
A previous study from the Long Life Family Study (LLFS), which
selected families characterized as healthy and having a strong his-
tory of longevity, showed that probands and offspring had higher
HDL levels and lower cardiovascular risk factors as compared
to similar aged individuals in the Cardiovascular Health Study
(Newman et al., 2011). Prospective studies have also found that
HDL levels in subjects who had survived to exceptional age were
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higher than those of their younger counterparts (Koropatnick
et al., 2008; Rahilly-Tierney et al., 2011). These studies suggest
that high levels of HDL may contribute to exceptional longevity,
likely due in part to reduction in CVD risk.
Genome-wide association (GWA) studies have allowed the
identification of many genetic loci that influence plasma levels
of HDL (e.g., Teslovich et al., 2010; Brautbar et al., 2011); how-
ever, the proportion of variance for HDL explained by these loci
remains low. We sought to identify genetic variants influenc-
ing HDL levels in a unique sample of families of exceptionally
healthy, elderly people from the LLFS, and to attempt to annotate
the function of any associated variants using the Encyclopedia of
DNA Elements (ENCODE) resources.
MATERIALS AND METHODS
STUDY DESIGN
The LLFS (https://dsgweb.wustl.edu/llfs/) was designed to deter-
mine genetic, behavioral, and environmental factors related to
families of exceptionally healthy, elderly individuals. Families
were sampled from four clinical centers: Boston University
Medical Center in Boston MA, Columbia College of Physicians
and Surgeons in New York City NY, the University of Pittsburgh
in Pittsburgh PA, USA, and University of Southern Denmark,
Denmark. The study characteristics, recruitment, eligibility and
enrollment have been previously described (Pedersen et al., 2006;
Sebastiani et al., 2009; Newman et al., 2011). In brief, the LLFS
recruited selected families with multiple exceptionally old living
individuals, totaling 4559 individuals, which included long-lived
probands and their siblings (n = 1445), their offspring (n =
2329) and spouse controls (n = 785). The probands were at least
79 years old in the USA centers, and 90 years old or above
in Denmark. The families were selected to participate in the
study based on The Family Longevity Selection Score (FLoSS)
(Sebastiani et al., 2009) which calculated the rank sibships by
current age or age at death of siblings, the size of the sib-
ship and the number of alive individuals available for study. A
proband’s family was FLoSS eligible if reached a score of 7 or
higher, which met the following criteria: (1) the proband, at
least one living sibling, and one of their living offspring (min-
imum family size of 3) were all able to give informed consent,
and (2) were willing to participate in the interview and examina-
tion including the blood sample for serum and DNA extraction.
A broad range of phenotypes were assessed, such as: validated
age (by driver’s license, birth certificate, or other official doc-
ument or source), anthropometric measures, blood pressure,
lipids, glucose metabolism, lung function, physical, and perfor-
mance functions (e.g., difficulty with activities of daily living,
instrumental activities of daily living, mobility, gait speed, chair
stands and standing balance, and strength), cognitive testing, edu-
cation, behavior (e.g., smoking and alcohol intake), and history of
disease (e.g., heart disease, stroke, hypertension, diabetes, chronic
lung disease, peripheral artery disease, and cancer) among other
traits. Reported medications, including anti-hypertensives, anti-
anginals, oral hypoglycemics and insulin, and lipid lowering
drugs, were confirmed by medication inventory of all pre-
scriptions and over-the-counter medications taken in the past
2 weeks.
PHENOTYPE
HDL was measured directly in serum using the Roche HDL
3rd generation direct method (Roche Diagnostics, Indianapolis,
IN 46250) on a Roche Modular P Chemistry Analyzer (Roche
Diagnostics Corporation).
GENOTYPE
The genotype data included ∼2.3 million SNPs from the
Illumina Omni chip. Quality control was performed before
imputation by checking pedigree relationships using GRR
(Abecasis et al., 2001) and Loki (Heath, 1997) approaches.
Single-nucleotide polymorphism (SNPs) were eliminated if
presented Mendelian errors, coded allele frequency <1%
or >99%, deviations from Hardy-Weinberg equilibrium (p <
1.0 × 10−6), and/or low call rate (98%). Approximately 2 mil-
lion autosomal SNPs remained after genotype quality control.
Imputation was performed on phased 1000 Genomes with
Cosmopolitan data as a reference (version 2010-11 data freeze,
2012-03-04 haplotypes; http://www.sph.umich.edu/csg/abecasis/
MaCH/download/1000G.2012-03-14.html) and using MACH
and MINIMAC to perform the imputation (http://www.sph.
umich.edu/csg/abecasis/mach/). This process led to a hybrid
dataset with 38,245,546 SNPs, of which 2,225,338 SNPs were
genotyped and 36,020,208 SNPs were imputed.
COVARIATE ADJUSTMENT
Cryptic stratification was accounted for by estimating the first
20 principal components (PCs, EIGENSTRAT (Price et al., 2006)
in genotype data with the highest call rates in 1522 independent
individuals. The PC models were then applied to the remaining
(non-independent) family members. HDL levels were adjusted
using two steps: (1) forcing field centers into the regression anal-
ysis, and then (2) adding age, age2, and twenty PCs within sex
groups using a stepwise regression analysis and retaining terms
significant at the 5% level. Residuals were normalized to have
mean 0 and standard deviation 1, and normalized residuals were
used as phenotypes to test for genotype-phenotype association.
ASSOCIATION ANALYSIS
GWA scan was carried out assuming additive effects with mixed
model linear regression, accounting for dependency among fam-
ily members as a function of their kinship correlations (R kin-
ship package: http://cran.r-project.org/web/packages/GWAF/).
Results were filtered to include SNPs with acceptable imputation
quality (r2 MACH> 0.3) and with effect allele frequency between
1–99%. After genotype data filtering, a total of ∼9.4M SNPs were
taken in the GWA results.
REGIONAL PLOT
Regional plots were generated with LocusZoom (Pruim et al.,
2010) for investigation of linkage disequilibrium (LD) and block
structure based on hg19/1000 Genomes March 2012-EUR.
BIONFORMATIC ANALYSES
To investigate the functions of our candidate SNPs
(Table 1), such as, type-specific patterns of promoters and
enhancers, and their regulatory motif enrichment and
regulator expression, we used the ENCODE Consortium
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Table 1 | Characteristics of the variables studied in the GWA analysis.
Variables Men Women
Sample size (%) 1858 (45.2) 2256
Age (years) 70.8±15.2 69.6±16.0
Body mass index (kg/m2) 27.5±4.1 26.7±5.3
Fasting levels of HDL (mg/dL) 52.6±15.1 64.5±17.2
Lipid-lowering medication (%) 40.4 35.0
Variables are shown as number (N), and/or frequency (%), or mean ± standard
deviation.
(https://genome.ucsc.edu/ENCODE/), the Roadmap Epigenome
Mapping Consortium (http://www.ppmroadmap.com/) and
the Single Nucleotide Polymorphism Database (dbSNP, https://
www.ncbi.nlm.nih.gov/SNP/), as implemented in HaploReg (v2,
www.broadinstitute.org/mammals/haploreg/; Ernst et al., 2011)
and RegulomeDB (www.regulomedb.org/; Boyle et al., 2012).
RESULTS
Table 1 shows the characteristics of 4114 subjects of European-
American individuals (480 families) from the LLFS that partic-
ipated in the GWA analyses. The mean levels of age and BMI
were not significantly different in men as compared to women.
However, the proportion of subjects taking lipid-lowering medi-
cations in men is higher than in women, while the mean levels of
fasting plasma levels of HDL are higher in women than men. The
distribution of mean levels of HDL in the sex-combined data is
depicted in Supplementary Figure 1.
The estimated GWA inflation (λGC) for HDL was 1.03, indi-
cating that there was no significant population stratification.
Also, there were results that exceeded the genome-wide signif-
icant threshold (p < 5.0E-08), suggesting the effect of variants
influencing HDL levels (Supplementary Figure 2).
On chromosome 17p13, we found statistical evidence for a
novel variant near-NLRP1 (rs12450571: p = 1.82E-08, β = 0.13,
minor allele frequency (maf) of G allele=0.47) influencing fast-
ing plasma levels of HDL. In addition, we detected association
of variants in ZNF259-APOA5-A4-C3-A1 [11q23.3, rs3741298:
p = 2.04E-08, β = −0.16, maf(C) = 0.21] and HERPUD1-CEPT
(16q21, rs72786786: p = 3.64E-26, β = −0.28, maf (A) = 0.32]
with HDL, which were previously reported in the literature (e.g.,
Teslovich et al., 2010; Brautbar et al., 2011). The regional plots
show the LD and block structures for SNPs on 17p13 (Figure 1A),
on 11q23.3 (Figure 1B) and on 16q21 (Figure 1C). Table 2 shows
the SNPs with the strongest associations with HDL levels in each
chromosome region, while the Supplementary Table 1 lists all
associated SNPs.
BIONFORMATICS
Using the ENCODE, Roadmap and dbSNP data in RegulomeDB
and HaploReg, we assessed the annotations of the novel find-
ings near-NLRP1 on 17p13 (Supplementary Table 2). The variants
rs12450571, rs8080616, and rs2215496 were suggested to have a
role in binding motif (SEF-1, Foxj1, Foxa, Foxk1, Foxo, Foxp1,
HDZC2, HMG, Irf, Nanog, Sox, p300, and/or Pou2f2; Matys
et al., 2006; Badis et al., 2009; Scharer et al., 2009), and in
methylating histones (H3k09me3, H4k20me1, H3k27me3, H2az,
and H3k9me1). The rs12450571 SNP was also suggested to inter-
act with chromatin remodeling in cell lines (HUES6, ES-I3,
and iPS-15b). The ZNF259-rs3741298 and HERPUD1-CEPT-
rs72786786 were implicated in ENCODE DNAse and regulatory
chromatin states associated with diseases, in binding proteins, in
histone methylations and in motif changes (Supplementary Table
2). These annotations suggest that the HDL-associated variants
found in the LLFS subjects are involved in genetic regulatory
functions.
DISCUSSION
Our current study, focusing on GWA, demonstrated evidence
of genes associated with fasting plasma levels of HDL choles-
terol, which have been linked to inflammation, apoptosis and/or
longevity (Barzilai et al., 2006; Bergman et al., 2007; Jin et al.,
2007; Magitta et al., 2009; Sanders et al., 2010; Zurawek et al.,
2010; Dieudé et al., 2011). We have identified novel variants
near-NLRP1 (NLR family, pyrin domain containing 1; 17p13)
associated with an increase in HDL levels, and also repli-
cated associations for HDL with several established variants
in HERPUD1-CEPT (16q21) and ZNF259-APOA5-A4-C3-A1
(11q23.3) (Teslovich et al., 2010; Brautbar et al., 2011). The vari-
ants in CEPT (cholesteryl ester transfer protein) and APOC3
(apolipoprotein C3) genes have been connected with healthy
aging, in addition to associations with HDL levels. CETP V405
homozygosity was associated with slower memory decline and
lower incidence of dementia and Alzheimer disease risk in healthy
older adults compared with controls in the Einstein Aging Study
(Sanders et al., 2010). In Ashkenazi Jews from the Longevity Gene
Study, high levels of HDL and its large lipoprotein sizes were over
represented in centenarians, as well as the prevalence of homozy-
gosity for I405V-CETP and 641C-APOC3 in both centenarians
and their offspring than in the controls (Barzilai et al., 2006;
Bergman et al., 2007). We also found high levels of HDL and a
borderline higher prevalence of homozygosity for 641C-APOC3
(rs2542052: p = 0.06) in the healthy LLFS subjects as compared
to an independent data from the Family Heart Study (N = 3794
European-Americans) that has approximately half families CVD-
selected and the other half families randomly-selected. While the
findings have reproducibly demonstrated that HDL levels are high
in healthy-longevous populations, we have only begun to identify
the underlying genetic factors.
Association of multiple variants in the intergenic region and
within NLRP1 have been reported to be associated with innate
immunity/inflammasome disorders, including vitiligo (Jin et al.,
2007), Addison’s disease (Zurawek et al., 2010), systemic sclero-
sis -related pulmonary fibrosis (Dieudé et al., 2011), and type
1 diabetes (Magitta et al., 2009). It is interesting to note that
some of the NLRP1-intergenic SNPs for vitiligo and other dis-
eases [including systemic lupus erythematosus (SLE); (Jin et al.,
2007)] also showed suggestive associations for HDL in LLFS (e.g.,
rs995298: p = 7.09E-06, rs8065677: p = 2.98E-04, rs2716900:
p = 4.28E-04). These SNPs are in moderate LD (r2 = 0.30 –
0.57) with the HDL-associated SNPs (rs12450571, rs8080616, and
rs2215496) reported in the present study, suggesting that this
expanded region may be relevant to these multiple phenotypes.
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FIGURE 1 | Regional plots represent the associations between plasma
levels of HDL and NLRP1 (A), ZNF259 (B), and CEPT (C) gene
regions. The −log10 (p-value) for HDL is represented in the ordinate
axis, while the chromosome position in Megabase (Mb) using build 37.3
is represented in the abscissa axis. The bottom panels give the relative
positions of genes in the locus. Purple diamond indicates the effect of
the top significant SNP with HDL cholesterol. Each circle indicates a SNP
with the color of the circle representing the correlation (r2) between that
SNP and the top significant SNP. Blue line indicates estimated
recombination hotspots.
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Table 2 | GWA results for the most significant SNP (p < 5.0E-08) at each locus for plasma levels of HDL.
SNP Chr Location CA CAF IP Gene Function N β SE P
rs3741298 11 116657561 T 0.79 1 ZNF259 intron 4114 0.16 0.03 2.04E-08
rs12450571 17 5636654 G 0.47 0 near-NLRP1 4110 0.13 0.02 1.82E-08
rs72786786 16 56985514 A 0.32 1 near-CETP 4114 0.28 0.03 3.64E-26
Chr, chromosome; Location, in Megabase using build 37.3; CA, coded allele; CAF, coded allele frequency; IP, Imputed SNP is represented as “Y” (“N” = typed); β,
regression coefficient for the coded allele; SE, Standard error of the β; P, P value of association.
It is widely recognized that low HDL levels are risk factors
for atherosclerosis, which is also a major co-morbid condition
in autoimmune diseases (Skaggs et al., 2010). Low HDL lev-
els and insulin resistance were significantly increased in patients
with vitiligo (Karadag et al., 2011), and a dysfunctional, pro-
inflammatory form of HDL (piHDL) was present in 45% of SLE
patients vs. 4% of controls (McMahon et al., 2006).
There is also evidence linking NLRP1 to longevity (Flachsbart
et al., 2010), Alzheimer disease (Pontillo et al., 2012), and
CVD (Garg, 2011), suggesting it interacts with other lipid
related-genes (Sanz et al., 2004; Im et al., 2011). A study
demonstrated that SREBP-1a (sterol regulatory element bind-
ing proteins, 17p11) links lipid metabolism to the macrophage
innate immune response through Nlrp1a, a mouse ortholog
of human NLRP1 (Im et al., 2011). SREBP-1a is required for
lipopolysaccharide-stimulated interleukin 1β (IL1β) production,
which occurs by SREBP-1a activating the expression of the Nlrp1a
gene through a binding site in its proximal promoter. SREBP-
1a proteins belong to a small family of transcription factors
and are key regulators of cellular lipid levels. Im et al. (2011)
proposed that SREBP-1a evolved to directly regulate genes of
the innate immune response in macrophages because cell pro-
liferation and membrane expansion/ rearrangements are both
essential in the macrophage response to pathogen challenge and
both require new lipid synthesis. The lipid levels are critical
for cell-environment interactions in macrophages, and regula-
tion of lipid concentration and composition is fundamental to
optimize protein-lipid microenvironments required for trans-
port, signaling, internalization, and shape alterations such as
blebbing and invagination. Other studies in myeloid leukaemia
cells proposed that NLRP1 and CREB (cAMP-response-element-
binding protein) may contribute by modulating the response
to pro-inflammatory stimuli. NLRP1 was found to be tran-
scriptionally regulated by CREB transcription factor in myeloid
cells (Sanz et al., 2004). CREB has also been associated
with COX-2 (cyclooxygenase-2) expression, which in turn is
induced by HDL in vascular endothelial cells through a bioac-
tive lysophospholipid SphK-2 (sphingosine kinase-2) (Xiong
et al., 2014). The COX-2 enzyme is responsible for inflam-
mation and pain and has been reported to exert cardiopro-
tective effects in a model of myocardial ischemia–reperfusion
injury via activating PGI-2 (prostaglandin I-2) synthesis (Bolli
et al., 2002). These findings may suggest that all these com-
ponents, including NLRP1 gene region, possibly contribute to
HDL anti-atherogenic effects; however, the mechanisms involved
remain largely unknown and more in-depth investigations are
needed.
The NLRP1 (also called as NALP1) is a member of NLR
(nucleotide-binding domain leucine-rich repeat containing)
multi-domain proteins family of intracellular sensors. NLRP1
encodes a protein that contains a N-terminal pyrin-like motif,
which may be involved in protein-protein interactions and play
a role in regulating the apoptotic machinery. NLRP1 recruits
the adapter protein ASC (apoptosis-associated speck-like protein
containing CARD), caspase 1, and caspase 5 to a complex termed
the NLRP1 inflammasome, which activates the proinflamma-
tory cytokine, pro-IL1β. Pyrin-like motif is conserved with other
mammalian proteins such as ASC, and is evolutionarily conserved
across other species, as seen in sequence alignments with zebrafish
ASC1 (Hlaing et al., 2001). In various human populations,
Vasseur et al. (2012) studied germline-encoded microbial sen-
sors characterizing the levels of genetic sequence diversity of the
central nucleotide-binding domain termed NACHT. The authors
identified NLRP1 amino acid changes that conferred a positive-
selective advantage related to microbial sensing in Europe, Africa,
and Asia. Also, they detected another NLRP1 positive-selection
event restricted to Europe. Some of the selective advantageNLRP1
variants have shown association with various autoimmune dis-
eases, including Addison’s disease, type I diabetes, and vitiligo,
which may suggest that variants in the intergenic region and
withinNLRP1may cause differences in susceptibility to infections
(Hlaing et al., 2001; Vasseur et al., 2012) and immunity-related
disorders (Jin et al., 2007).
ENCODE annotation of our novel near-NLRP1 variants
(rs12450571, rs8080616, and rs2215496) associated with
HDL levels suggested they may have a regulatory function
(Supplementary Table 2). Glinskii et al. (2009) studied inter-
genic trans-regulatory RNAs containing a disease-linked SNP
sequence and demonstrated that another NLRP1 intergenic
SNP (rs2670660) was expressed in human cells, encoding a
small RNA. The expression of rs2670660-encoded transRNAs
triggered concomitant activation of the polycomb pathway
genes which catalyzed histone H3K27me3. Rs2670660 alters
predicted binding motifs for the transcription factors HMGA1
[HMG-I(Y)] and MYB. Although our near-NLRP1 SNPs are in
very low LD (r2 < 0.04) with rs2670660, there are other reported
associated SNPs in the expanded NLRP1 region that may have
regulatory function. It is worthy to mention that our near-NLRP1
SNPs were also suggested to participate in histone methylation
(H3k09me3, H4k20me1, H3k27me3, H2az, and H3k9me1) and
as a binding motif (rs8080616) for HMG (high-mobility group).
While further studies are needed, these data suggest that this is a
conserved regulatory region that may influence NLRP1 or other
genes residing near 17p13.
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Our study has several relevant strengths and limitations. It is a
large family study of exceptionally healthy and well-characterized
longevous subjects. Data published from the Global Lipid Genetic
Consortium did not report SNPs meeting genomewide crite-
rion influencing HDL in this region, thus, our novel finding of
NLRP1 intergenic SNPs associated with HDL requires replica-
tion. Despite the resources for annotation available, it is not clear
whether our HDL-associated intergenic SNPs regulate NLRP1 or
even other more remote genes. Our SNPs, however, are in mod-
erate LD with NLRP1 intergenic SNPs that were associated with
immunity/inflammasome disorders, which underscores the bio-
logical importance of this region. There is also published evidence
that NLRP1 interacts with genes (SREBP-1a and CREB) likely
associated with lipid metabolism, apoptosis, autoimmune and/or
autoinflammatory diseases, factors that likely influence HDL lev-
els and longevity. Thus, our findings may provide new insights
into the biological regulation of HDL metabolism and longevity
that deserve further investigations.
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